oncosil MEDICAL

Investor Update

Advancing pancreatic cancer treatment
Transforming the prognosis

February 2021

oncosil MEDICAL

Transforming the prognosis

OncoSil will be a market leader in pancreatic cancer therapy, aimed at extending the length and quality of life of patients

Introduction to Nigel Lange

- 35+ years' experience in pharmaceutical and medical device industries
- Served as Europe CEO, Group COO and Interim Group CEO of Sirtex Medical, a global leader in brachytherapy treatment for liver cancer
- Clear understanding of pathway to successful device launch and uptake
- Extensive experience launching SIR-Spheres™ and TheraSphere™ technologies in US and Europe
- Familiar with Australian market and business environment
- Proven leadership in ASX-listed company[1]

> ***I am delighted to be appointed as CEO as I firmly believe in the technology and the critical role it plays in this area of unmet clinical need.***

1. Sirtex Medical was an ASX-listed company, prior to being acquired for ~A$1.9bn in 2018

An exciting and attractive outlook for OncoSil

PanCO study success	• PanCO was a single-arm study designed to obtain regulatory approval • The study was successful, with CE Marking approval granted in April 2020
Promising downstaging data	• PanCO results highlighted the impact of downstaging patients to surgical resection • Although downstaging was not planned, the 23.8% downstaging rate exceeds that in published phase 2/3 trials, comparing favourably to standard-of-care
Large, unmet need	• Prognosis of pancreatic cancer remains poor; current treatment methods are relatively ineffective • Opportunity for OncoSil™ to become the standard-of-care, supported by our breakthrough designation by FDA and in Europe
Experienced team	• Experienced and accomplished commercial team in Europe and US • Proven track records in the medical devices industry, able to leverage key existing relationships in the market (medical oncology, HPB surgery, nuclear medicine)

oncosil MEDICAL

Key activities over the past 6 months

TEAM FINALISED

- ✓ Functions recruited include key account managers, training manager, chief medical officer, global head of medical affairs, health economics and reimbursement/market access

SUPPORTING APPLICATIONS

- ✓ Submitted additional data to the TGA (Australia) in January 2021, as requested
- ✓ Preparing updated data package for the FDA to support HDE application

OSPREY APPROVAL RECEIVED

- ✓ Formal approval received from HRA and REC in UK for 9 sites
- ✓ Progressing steps to establish OSPREY registry in other regions



COVID-19 DELAYS

- ✓ COVID-19 has impacted approval timelines for many authorities/countries
- ✓ Limited-to-no access to hospitals has delayed launch, including onboarding, training and marketing activities at these sites

oncosil MEDICAL

Growth priorities

Strategic priorities for OncoSil – EMEA and APAC

1 Supporting Key institutions

- Support 9 UK hospitals in London and Greater London to facilitate ramping up of patient treatments
- Initial focus on private payer market in EMEA and APAC as a primary source of early revenue
- Facilitating local ethics approvals for the OSPREY registry in other jurisdictions

2 Targeting reimbursement in key markets

- Comparative data is required to support reimbursement in the public sector
- While compelling, the PanCO study represents single-arm, non-comparative data
- OncoSil is developing a strategic clinical plan to meet these requirements – focusing on Germany and the UK

3 Capitalising on CE Marking approval

- CE Marking approval is recognised by many jurisdictions in EMEA and APAC
- OncoSil will continue to leverage its CE Marking and seek approvals in selected markets

oncosil MEDICAL

Growth priorities

Strategic priorities for OncoSil – US

4 Immediate focus on HDE pathway for distal bile duct cancer

- Cost-effective, rapid pathway for entry into world's largest healthcare market
- HDE requirements are limited to a lower level of evidence, using pancreatic cancer data as a surrogate
- Once HDE is approved, OncoSil™ will be eligible for reimbursement through CMS
- Once CMS is approved, third-party reimbursement would follow

5 Develop strategy for PMA in locally advanced pancreatic cancer

- FDA affords the opportunity for OncoSil to work collaboratively and seek guidance on clinical trial design of a Phase II/III trial to support pre-market application (PMA)
- FDA breakthrough device designation coupled with CMS final rule ensures a reimbursement pathway for 4 years minimum[1]

1. Final MCIT rule is currently being established as part of EO 13890. Current proposal of MCIT rule will provide national Medicare coverage as early as the same day as PMA approval for breakthrough designated devices, for a period of 4 years with scope to extend.

Building our Commercial and Clinical Expertise

Additions critical to OncoSil as we commence global commercialisation

Dr. Ralph Peters

Chief Medical Officer

- 30+ years of experience in diagnostic and interventional radiology
- EMEA Medical Director of Sirtex Medical from 2005 - 2020
- Responsibilities at Sirtex included clinical development and support, market access and reimbursement, regulatory workstreams, site training and proctoring

Mr. David Turner

Head of Medical Affairs

- 40+ years experience in pharmaceutical, medical device and health technology industries
- 25+ years in commercial leadership roles including board and senior executive positions
- Most recently, David served as Global Head of Marketing for Sirtex Medical

Mr. Olaf Michaelsen

Director, AREA[1]

- 25+ years experience in implantable medical devices
- Previously held commercial leadership roles at Sirtex Medical, Medtronic and LifeCell
- 20+ years experience in market access, reimbursement, health economics and technology assessments in Europe

oncosil MEDICAL

1. Access Reimbursement / Economics / Assessment

Important notice

This Presentation has been prepared by OncoSil Medical Ltd (ASX:OSL) (**OncoSil** or the **Company**) to provide a general overview of the Company. This Presentation and the information contained may require further explanation and/or clarification. Accordingly, this Presentation and the information contained should be read in conjunction with past and future ASX announcements made by OncoSil and should not be relied upon as an independent source of information. Please contact OncoSil and/or refer to the Company's website www.oncosil.com.au for further information.

Not an Offer for Securities

Nothing in this Presentation constitutes investment advice or should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in the Company, in any jurisdiction. This presentation is not exhaustive of all of the information a potential investor or their professional advisers would require. This presentation does NOT constitute a “Prospectus" or a "Disclosure Document” (as defined in the Corporations Act 2001 (Cth) (Corporations Act)) and has not been, and will not be, lodged with the Australian Securities and Investments Commission or any other regulatory authority. Accordingly, it is not required to contain, and may not necessarily contain, all of the information that a Prospectus or like Disclosure Document would be required to contain pursuant to the Corporations Act.

Forward-Looking Statements

This document contains certain forward-looking statements as at the date of this presentation relating to OncoSil’s business, which can be identified by the use of forward-looking terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”, “expected”, “estimated”, “targeting”, “aiming”, “set to”, “potential”, “seeking to”, “goal”, “could provide”, “intends”, “is being developed”, “could be”, “on track”, or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA and other national and international authorities’ requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales, nor that that any specific objective of the Company will be achieved or that any particular performance of the Company or of its shares will be achieved. In particular, the Company's expectations regarding the approval and commercialisation of the product candidates could be affected by, amongst other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; changes in legislation or regulatory requirements, our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our Company, products, product candidates, financial results and business prospects. Should one or more of these changes, risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. OncoSil is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise. There is NO guarantee of future performance - actual results and future outcomes will in all likelihood differ from those outlined herein. You are urged to consider all of the above and advice from your own advisers carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on the forward-looking statements. The information in this presentation is not financial product advice, is not an offer to invest in the securities of OncoSil and does not take into account your investment position or objectives, financial situation or any particular requirements. For these and other reasons, you are strongly recommended to obtain your own up to date independent legal, financial and investment advice – those acting without such advice do so at their own risk.

Disclaimer

This Presentation and any supplemental materials have been prepared by OncoSil based on available information. Although reasonable care has been taken to ensure the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness, or correctness of such information and opinions and no reliance should be placed on such information or opinions. To the maximum extent permitted by law, none of OncoSil or any of its members, directors, officers, employees, or agents or corporate advisors, nor any other person accepts any liability whatsoever for any loss, however arising, from the use of the presentation or its contents or otherwise arising in connection with it, including, without limitation, any liability arising from fault or negligence on the part of OncoSil or any of its directors, officers, employees or agents.

The information contained in this presentation is current as at 18 February 2021.

Nigel Lange
CEO & Managing Director
E: nigel.lange@oncosil.com

OncoSil Medical Ltd
www.oncosil.com

T: +49 30 300 149 3043

oncosil
MEDICAL